Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14119393 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| Bromide SCHEMBL9517907 | 0.98 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL7122888 | 0.82 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL3273982 | 0.76 | KMT2A (0.38) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL13779317 | 0.74 | RAB9A (0.65) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL24163129 | 0.67 | CSNK2A2 (0.38) | ALDH1A1KMT2AMEN1KDM4EPOLB | |
| SCHEMBL3889066 | 0.66 | INMT (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL6950367 | 0.65 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1KDM4EPOLB | |
| Bromide SCHEMBL1668833 | 0.64 | ALDH1A1 (0.35) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL9437077 | 0.64 | KMT2A (0.38) | SMN1; SMN2ALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-7585876-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1744720-B1 | KERATIN DYEING COMPOSITIONS CONTAINING bicyclic 5-5 heteroaromatic compounds | PROCTER & GAMBLE (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1456206-B1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-05-15 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7229480-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229480-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1455779-B1 | INDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040209867-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-10-21 | — | — | US | disclosed |
| US-6800640-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-10-05 | — | — | US | disclosed |
| EP-1455779-A1 | INDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1456206-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6770642-B2 | FOR USE IN TREATMENT OF CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, EPILEPSY, OBSESSIVE COMPULSIVE DISORDER, ATTENTION DEFICIT DISORDER, MIGRAINE, COGNITIVE MEMORY ENHANCEMENT, ALZHEIMER'S DISEASE | WYETH | 2004-08-03 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
| US-20030171353-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
| WO-2003053433-A1 | INDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053970-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | SMN1; SMN2 3120/4885NPC1 1168/4885RAB9A 3857/4885 |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | SMN1; SMN2 1475/4885NPC1 3296/4885RAB9A 3286/4885 |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | SMN1; SMN2 4071/4885NPC1 2643/4885RAB9A 2746/4885 |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR7 | SMN1; SMN2 4169/4885NPC1 3052/4885RAB9A 2693/4885 |
| US-20040209867-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | SMN1; SMN2 3605/4885NPC1 794/4885RAB9A 2884/4885 |
| US-20030171353-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | SMN1; SMN2 3605/4885NPC1 794/4885RAB9A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.